Method for extracorporeal removal of pathogenic microbe, an inflammatory cell or an inflammatory protein from blood

• US 10,188,783 B2
• Filed: 08/16/2017
• Issued: 01/29/2019
• Est. Priority Date: 12/13/2005
• Status: Active Grant

• Current Assignee: ExThera Medical Corporation
• Original Assignee: ExThera Medical Corporation
• Inventors: Larm, Olle, Bergstrom, Tomas
• Primary Examiner(s): Mondesi, Robert B
• Assistant Examiner(s): Meah, Mohammad Y
• Application Number:
  US15/678,580
• Publication Number:
  US 20170340803A1
• Time in Patent Office: 531 Days
• Field of Search: 435 6, 435 2, 435372, 424529, 4242041, 4241401
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61M 1/3679 by absorption A61M1/3675 takes precedence
• CPC Class Codes: A61M 2202/0413 Blood
• CPC Class Codes: A61M 2202/203 Bacteria
• CPC Class Codes: A61M 2202/206 Viruses
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 33/06 Antimalarials
• CPC Class Codes: A61P 7/08 Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a method for extracorporeal removal of a pathogenic microbe, an inflammatory cell or an inflammatory protein from mammalian blood/use of a device comprising a carbohydrate immobilized on a solid substrate, said carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, for extracorporeal removal of said pathogenic microbe, inflammatory cell or inflammatory protein from mammalian blood/use of a carbohydrate having a binding affinity for a pathogenic microbe, an inflammatory cell or an inflammatory protein, wherein said carbohydrate is immobilized on a solid substrate, in the preparation of a device for treatment of a condition caused or aggravated by said pathogenic microbe, inflammatory cell or inflammatory protein and a method for treatment of a mammalian subject suffering from a condition caused or aggravated by a pathogenic microbe, an inflammatory cell or an inflammatory protein.

Claims

1. A method for extracorporeal removal of a virus from a subject, said method comprising:

a) contacting said subject'"'"'s whole blood with heparin immobilized on a solid substrate, said heparin having a terminal residue, wherein heparin immobilization consists of a single covalent link of said terminal residue to said solid substrate by covalent end-point attachment, under conditions allowing binding of said virus in said subject'"'"'s whole blood sample to the heparin;

b) separating the whole blood from the solid substrate;

c) recovering said whole blood containing a reduced amount of said virus; and

d) reintroducing into said subject said whole blood containing a reduced amount of said virus.

2. The method of claim 1, wherein said solid substrate comprises microparticles.

3. The method of claim 1, wherein said solid substrate comprises fibers.

4. The method of claim 1, wherein the material of said solid substrate is at least one member selected from the group consisting of glass, cellulose, cellulose acetate, chitin, chitosan, crosslinked dextran, crosslinked agarose, polypropylene, polyethylene, polysulfone, polyacrylonitrile, silicone, Teflon and polyurethanes.

5. The method of claim 1, wherein said virus is selected from the group consisting of herpes simplex virus type 1, herpes simplex virus type 2, Influenza A virus, cytomegalovirus and human immunodeficiency virus.

6. The method of claim 5, wherein said virus is selected from the group consisting of herpes simplex virus type I and herpes simplex virus type 2.